TY - JOUR
T1 - Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary
T2 - A retrospective Japan Clear Cell Carcinoma Study
AU - Takano, M.
AU - Sugiyama, T.
AU - Yaegashi, N.
AU - Sakuma, M.
AU - Suzuki, M.
AU - Saga, Y.
AU - Kuzuya, K.
AU - Kigawa, J.
AU - Shimada, M.
AU - Tsuda, H.
AU - Moriya, T.
AU - Yoshizaki, A.
AU - Kita, T.
AU - Kikuchi, Y.
PY - 2008/9/1
Y1 - 2008/9/1
N2 - Clear cell carcinoma (CCC) of the ovary has been recognized to show resistance to anticancer agents in the first-line chemotherapy. Our aim was to evaluate the effect of second-line chemotherapy in a retrospective study. A total of 75 patients diagnosed with CCC and treated between 1992 and 2002 in collaborating hospitals were reviewed. Criteria for the patients' enrollment were 1) diagnosis of pure-type CCC at the initial operation, 2) treatment after one systemic postoperative chemotherapy, 3) measurable recurrent or refractory tumor, 4) at least two cycles of second-line chemotherapy and assessable for the response, and 5) adequate clinical information. Regimens of first-line chemotherapy were conventional platinum-based therapy in 33 cases, paclitaxel plus platinum in 24 cases, irinotecan plus platinum in 9 cases, and irinotecan plus mitomycin C in 7 cases. Treatment-free periods were more than 6 months in 24 cases (group A) and less than 6 months in 51 cases (group B). In group A, response was observed in two cases (8%): one with conventional platinum therapy and another with irinotecan plus platinum. In group B, three cases (6%) responded: two with platinum plus etoposide and one case with irinotecan plus platinum. Median overall survival was 16 months in group A and 7 months in group B (P = 0.04). These findings suggest recurrent or resistant CCC is extremely chemoresistant, and there is only small benefit of long treatment-free period in CCC patients. Another strategy including molecular-targeting therapy is warranted for the treatment of recurrent or refractory CCC.
AB - Clear cell carcinoma (CCC) of the ovary has been recognized to show resistance to anticancer agents in the first-line chemotherapy. Our aim was to evaluate the effect of second-line chemotherapy in a retrospective study. A total of 75 patients diagnosed with CCC and treated between 1992 and 2002 in collaborating hospitals were reviewed. Criteria for the patients' enrollment were 1) diagnosis of pure-type CCC at the initial operation, 2) treatment after one systemic postoperative chemotherapy, 3) measurable recurrent or refractory tumor, 4) at least two cycles of second-line chemotherapy and assessable for the response, and 5) adequate clinical information. Regimens of first-line chemotherapy were conventional platinum-based therapy in 33 cases, paclitaxel plus platinum in 24 cases, irinotecan plus platinum in 9 cases, and irinotecan plus mitomycin C in 7 cases. Treatment-free periods were more than 6 months in 24 cases (group A) and less than 6 months in 51 cases (group B). In group A, response was observed in two cases (8%): one with conventional platinum therapy and another with irinotecan plus platinum. In group B, three cases (6%) responded: two with platinum plus etoposide and one case with irinotecan plus platinum. Median overall survival was 16 months in group A and 7 months in group B (P = 0.04). These findings suggest recurrent or resistant CCC is extremely chemoresistant, and there is only small benefit of long treatment-free period in CCC patients. Another strategy including molecular-targeting therapy is warranted for the treatment of recurrent or refractory CCC.
KW - Ovarian clear cell carcinoma
KW - Recurrent
KW - Refractory
KW - Second-line chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=51749104422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51749104422&partnerID=8YFLogxK
U2 - 10.1111/j.1525-1438.2007.01158.x
DO - 10.1111/j.1525-1438.2007.01158.x
M3 - Article
C2 - 18081792
AN - SCOPUS:51749104422
VL - 18
SP - 937
EP - 942
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
SN - 1048-891X
IS - 5
ER -